Get started
Author

Jonathan Badrock

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
2021 · Wesley H. Self, Uriel Sandkovsky, et al. · The Lancet Infectious Diseases · 190
PDF
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
2018 · Marco Carbone, Alessandra Nardi, et al. · ˜The œLancet. Gastroenterology & hepatology · 156
PDF
Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study
2018 · Carbone, Marco, Nardi, Alessandra, et al. · HAL (Le Centre pour la Communication Scientifique Directe) · 120
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels
2021 · ACTIV-3/TICO Bamlanivimab Study Group*, Jens D. Lundgren, et al. · Annals of Internal Medicine · 77
PDF
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19
2022 · ACTIV-3/TICO Study Group, Angela J. Rogers, et al. · Annals of Internal Medicine · 60
PDF
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
2022 · Andrew R Clamp, Elizabeth C James, et al. · The Lancet Oncology · 47
PDF
The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis
2021 · Ben Barron‐Millar, Laura Ogle, et al. · Hepatology · 45
PDF
Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis
2023 · Laura Martinez-Gili, Alexandros Pechlivanis, et al. · Gut Microbes · 31
PDF
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
2022 · ACTIV-3/TICO Study Group*, Christina Barkauskas, et al. · Annals of Internal Medicine · 31
PDF
Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom
2020 · Stephen Rice, Viviana Albani, et al. · Clinical Gastroenterology and Hepatology · 30
REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers
2022 · Sophie Merrick, Matthew Nankivell, et al. · Contemporary Clinical Trials · 19
PDF
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19
2024 · Neil R Aggarwal, Jacquie Nordwall, et al. · Clinical Infectious Diseases · 15
PDF
Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells
2023 · Victoria Mulcahy, Evaggelia Liaskou, et al. · Hepatology Communications · 13
Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study
2024 · Tomas O Jensen, Thomas A Murray, et al. · The Lancet Microbe · 6
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19
2023 · Tomas O Jensen, Greg A Grandits, et al. · The Journal of Infectious Diseases · 4
PDF
805O ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment
2020 · A.R. Clamp, E.C. James, et al. · Annals of Oncology · 3
SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial)
2025 · Sofía Sábato, Susana Benet, et al. · Scientific Reports
Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells
2023 · Victoria Mulcahy, Evaggelia Liaskou, et al. · Newcastle University ePrints (Newcastle Univesity)
The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis
2021 · Ben Barron-Millar, Laura Ogle, et al. · Newcastle University ePrints (Newcastle Univesity)
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
2018 · Marco Carbone, Alessandra Nardi, et al. · Newcastle University ePrints (Newcastle Univesity)
Works count: 16
Citation count: 605
H-index: 12
I10-index: 12
Year
Topic
Type